AAAAI

AAAAI / WAO Joint Congress as we explore the critical intersection of climate change and allergic diseases and explore their profound global implications on health. You will learn from, and connect with, renowned experts from across the globe, discover cutting-edge research and make connections that will last a lifetime. Together, we'll turn ideas into action, connect with purpose and create lasting impact.

Conference Highlights
Expert Interviews
Featured
Dupilumab, Tezepelumab Gain Ground for Severe Asthma but Overall Biologic Adherence Rates Found Low: 2 Studies from 2025 AAAAI/WAO
Grace Halsey
February 12 2025
Postnatal Antibiotics for Maternal Indications May Heighten Childhood Asthma Risk
Sydney Jennings
February 12 2025
AAAAI 2025: Omalizumab Shows Favorable Outcomes Versus Oral Immunotherapy in Multi‐Food Allergy Treatment
Sydney Jennings
February 12 2025
Phase 3 Findings on Neffy for Pediatric Patients with Severe Allergies: A Conversation with Motohiro Ebisawa, MD, PhD
Sydney Jennings
March 4 2024
Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers
Grace Halsey
February 27 2024
New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares
Sydney Jennings
February 26 2024
Ethnic Minorities Found More Likely to Require Change in Biologic Therapy for Severe Asthma
Sydney Jennings
February 23 2024
EoE in Children Treated with Dupilumab More Severe at Diagnosis, Study Finds
Grace Halsey
February 23 2024
New Research Highlights Specific Allergens that May Predispose Sensitized Children with Asthma to Upper Respiratory Infections
Sydney Jennings
February 22 2024
New neffy Data on Clinical Efficacy Presented at 2024 AAAAI Annual Meeting
Grace Halsey
February 22 2024
Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improved Lung Function and Asthma Control, According to New Data
Sydney Jennings
February 21 2024
Dupilumab Effective Up to 5 Years in Adults with Moderate-to-Severe Atopic Dermatitis in Open-Label Extension Study
Grace Halsey
February 21 2024
First Study of Oral Mucosal Immunotherapy for Peanut Allergy Elicits Robust Immunologic Response in Adults
Grace Halsey
February 21 2024
Tezepelumab Demonstrates Sustained Post-Treatment Reductions in CSU Disease Activity, Inflammatory Markers
Grace Halsey
February 21 2024
Tezepelumab Effective in Severe Asthma Cohorts Stratified by Age at Onset, Inflammatory Phenotype, and Allergen Sensitization
Grace Halsey
February 24 2023
AAAAI 2023: Pediatric Asthma Risk Score Validated in Multi-cohort Study
Sydney Jennings
February 23 2023
For Persons with Asthma Infected with COVID-19, Systemic Corticosteroid Prescribing is Up
Grace Halsey
February 23 2023
AAAAI 2021: Asthma Not an Independent Predictor of Severe COVID-19 Outcomes
Sydney Jennings
March 5 2021
Significant Reductions in Exacerbations Seen in Broad Population of Severe Asthma Patients
Grace Halsey
March 1 2021
Expert-guided Online Decision Tool Supports Real-time Treatment Choice for Severe Asthma
Grace Halsey
March 1 2021
Asthma Patients with COVID-19 at Comparable Risk of Hospitalization
Grace Halsey
February 26 2021
Use of Face Masks Does Not Affect Oxygen Saturation in Asthma Patients
Grace Halsey
February 25 2021
AAAAI 2021 Virtual Annual Meeting: A First Look
Sydney Jennings
February 24 2021
Biologic Eliminates or Reduces Oral Steroids in Severe Asthma: PONENTE Trial
Grace Halsey
February 24 2021
© 2025 MJH Life Sciences

All rights reserved.